In Vitro Generation of Highly Infectious Recombinant Prions Adopting Structural Architectures of Bona Fide Prions

Why It Matters

Providing a scalable, in‑vitro source of infectious prions accelerates mechanistic research and drug discovery. Demonstrating that full structural fidelity is unnecessary reshapes prion biology.

Key Takeaways

• PMCA generates recombinant prions matching RML infectivity.
• Recombinant fibrils display V-shaped architecture similar to brain prions.
• C-terminal lobe differs from native prions yet remains highly infectious.
• Platform enables systematic structure‑activity studies of prion propagation.
• Demonstrates structural fidelity not required for prion pathogenicity.

Pulse Analysis

Prion diseases, such as Creutzfeldt‑Jakob and scrapie, have long challenged scientists because their causative agents are proteinaceous and lack nucleic acids. Recent cryo‑electron microscopy breakthroughs revealed that native prions share a parallel in‑register intermolecular β‑sheet (PIRIBS) fold with a distinctive V‑shaped topology. However, the field has struggled to reproduce these structures in the lab, limiting detailed mechanistic studies and the development of therapeutic interventions.

The newly reported PMCA‑based assay bridges this gap by amplifying recombinant PrPSc fibrils seeded with the RML strain. The amplified fibrils not only retain the high infectivity of their brain‑derived counterpart but also recapitulate the V‑shaped architecture observed in cryo‑EM studies. Notably, subtle differences persist in the C‑terminal lobe, yet these do not diminish pathogenicity, suggesting that prion infectivity tolerates structural variability. This finding refines the prevailing model that exact structural fidelity is a prerequisite for disease transmission.

By delivering a reproducible, high‑throughput source of infectious prions, the platform opens avenues for systematic structure‑activity investigations, screening of anti‑prion compounds, and exploration of strain diversity. Moreover, the methodology may be adapted to other protein‑misfolding disorders, offering a template for studying amyloidogenic processes beyond prions. As the scientific community seeks to translate structural insights into therapeutic strategies, this in‑vitro system represents a pivotal tool for accelerating discovery and informing public‑health responses.